Sponsor Pipeline

Novartis Pharmaceuticals Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-07-07
311
Active Trials
155
Recruiting
87
Phase 3
10
Disease Areas
124
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-07 NCT07465679
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With…
Trial completed
2026-07-07 NCT07465679
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With…
Enrollment increased: 500 -> 2508 participants
2026-07-07 NCT07635316
A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor…
Recruitment opened
2026-07-07 NCT05344469
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing…
Trial sites expanded: 129 -> 138 locations
2026-07-07 NCT05870579
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+…
Enrollment increased: 22 -> 28 participants
2026-07-03 NCT05827081
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Trial sites expanded: 220 -> 223 locations
2026-07-03 NCT02386800
CINC424A2X01B Rollover Protocol
overall status: "Recruiting" → "Active Not Recruiting"
2026-07-03 NCT02386800
CINC424A2X01B Rollover Protocol
Trial sites reduced: 101 -> 97 locations
2026-07-03 NCT07174063
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate…
overall status: "Recruiting" → "Active Not Recruiting"
2026-07-03 NCT07174063
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate…
Enrollment reduced: 15 -> 6 participants
2026-07-03 NCT07421167
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice…
date change Primary completion moved earlier: 2029-01-10 -> 2028-04-01
2026-07-03 NCT07421167
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice…
date change Completion moved earlier: 2030-09-18 -> 2030-08-08
2026-07-03 NCT05445843
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients…
Primary endpoint(s) modified
2026-07-02 NCT07598422
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients…
Recruitment opened
2026-07-02 NCT07598422
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients…
Enrollment increased: 5 -> 10 participants
2026-07-02 NCT07543120
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
Trial sites expanded: 7 -> 13 locations
2026-07-01 NCT07598448
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an…
date change Primary completion pushed: 2026-09-30 -> 2026-12-15
2026-07-01 NCT07598448
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an…
date change Completion pushed: 2026-09-30 -> 2026-12-15
2026-07-01 NCT06335979
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
overall status: "Recruiting" → "Active Not Recruiting"
2026-07-01 NCT04925479
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic…
date change Primary completion pushed: 2026-06-16 -> 2027-09-21
Showing 20 of 124 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-07-06 NCT07683065 A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD Not Yet Recruiting
2026-07-06 NCT07684469 Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care… Phase 4 Not Yet Recruiting
2026-07-02 NCT07681258 A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in… Not Yet Recruiting
2026-07-02 NCT07681271 A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib… Phase 2 Not Yet Recruiting
2026-07-01 NCT07679269 Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. Phase 2 Not Yet Recruiting
2026-06-30 NCT07677254 A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in… Not Yet Recruiting
2026-06-30 NCT07677267 A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC… Not Yet Recruiting
2026-06-24 NCT07665437 An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With… Phase 3 Not Yet Recruiting
2026-06-22 NCT07660055 Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors Phase 1 Recruiting
2026-06-22 NCT07660172 A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP… Phase 2 Not Yet Recruiting
Active Trials by Phase
Phase 4
23
Phase 3
85
Phase 2/3
2
Phase 2
59
Phase 1/2
26
Phase 1
37
Not specified
79
Active Trials — top 25 of 311
NCT IDTitleConditionStatus
Phase 4
NCT06501443 LATAM LOWERS LDL-C Hypercholesterolaemia Recruiting
NCT07034690 Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in… Atherosclerotic Cardiovascular Disease Recruiting
NCT06733922 ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS Relapsing Remitting Multiple Sclerosis (RRMS) Recruiting
NCT06372925 Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute… Plaque, Atherosclerotic Recruiting
NCT04638647 Secukinumab Open Label Roll-over Extension Protocol Autoimmunity, Inflammation Recruiting
NCT07489573 Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to… Hidradenitis Suppurativa (HS) Recruiting
NCT05803941 Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate… Prostate Cancer Recruiting
NCT04657822 Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior… Sickle Cell Disease Recruiting
NCT06824103 Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With… Graft vs. Host Disease Recruiting
NCT03340506 Dabrafenib and/or Trametinib Rollover Study Melanoma Recruiting
NCT04480853 Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing… Multiple Sclerosis Recruiting
NCT04877522 Asciminib Roll-over Study Chronic Myelogenous Leukemia Recruiting
NCT05090371 A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After… Relapsing-Remitting Multiple Sclerosis Active, Not Recruiting
NCT06941792 Inclisiran Effectiveness in China: a Pragmatic Randomized Trial Coronary Heart Disease Active, Not Recruiting
NCT07448610 ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants… Spinal Muscular Atrophy Not Yet Recruiting
NCT05622708 A Study of Secukinumab to Evaluate Maintenance of Response in Participants With… Non-radiographic Axial Spondyloarthritis Active, Not Recruiting
NCT02584933 Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib… ALK Positive Malignancies Active, Not Recruiting
NCT05252585 A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous… Renal Angiomyolipoma Active, Not Recruiting
NCT05161195 Roll-over Study to Allow Continued Access to Ribociclib Metastatic Breast Cancer Active, Not Recruiting
NCT06444113 Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of… Multiple Sclerosis Active, Not Recruiting
NCT02386800 CINC424A2X01B Rollover Protocol Primary Myelofibrosis Active, Not Recruiting
NCT03975829 Pediatric Long-Term Follow-up and Rollover Study Diffuse Astrocytoma Active, Not Recruiting
NCT07684469 Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care… Acute Coronary Syndrome Not Yet Recruiting
Phase 3
NCT05335876 Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in… Spinal Muscular Atrophy (SMA) Recruiting
NCT06597006 Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With… Familial Hypercholesterolemia - Homozygous Recruiting
View all 311 active Novartis Pharmaceuticals trials with filters →
Disease Areas
Get alerts when Novartis Pharmaceuticals's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free